Shares of Allergan plc (NYSE:AGN) have been assigned an average recommendation of “Buy” from the twenty-five ratings firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and seventeen have given a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $212.00.
AGN has been the topic of a number of research reports. Zacks Investment Research raised Allergan from a “hold” rating to a “buy” rating and set a $197.00 price objective on the stock in a research note on Wednesday, July 11th. Wells Fargo & Co reissued a “buy” rating on shares of Allergan in a research note on Tuesday, June 5th. Piper Jaffray Companies set a $161.00 price objective on Allergan and gave the stock a “hold” rating in a research note on Thursday, May 31st. Cantor Fitzgerald set a $180.00 price objective on Allergan and gave the stock a “hold” rating in a research note on Monday, June 11th. Finally, Deutsche Bank set a $210.00 price objective on Allergan and gave the stock a “buy” rating in a research note on Wednesday.
In related news, Director Joseph H. Boccuzi bought 900 shares of the business’s stock in a transaction dated Thursday, August 30th. The shares were bought at an average cost of $190.59 per share, with a total value of $171,531.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Christopher J. Coughlin bought 10,000 shares of the business’s stock in a transaction dated Thursday, September 6th. The shares were bought at an average cost of $190.64 per share, for a total transaction of $1,906,400.00. The disclosure for this purchase can be found here. 0.36% of the stock is owned by insiders.
Several institutional investors have recently made changes to their positions in AGN. Parnassus Investments CA grew its holdings in shares of Allergan by 3.1% during the second quarter. Parnassus Investments CA now owns 1,844,804 shares of the company’s stock valued at $307,566,000 after buying an additional 55,029 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Allergan by 2.9% during the second quarter. Bank of New York Mellon Corp now owns 3,545,557 shares of the company’s stock valued at $591,116,000 after buying an additional 99,490 shares in the last quarter. Arbor Wealth Management LLC grew its holdings in shares of Allergan by 92.8% during the first quarter. Arbor Wealth Management LLC now owns 13,846 shares of the company’s stock valued at $2,137,000 after buying an additional 6,663 shares in the last quarter. Toronto Dominion Bank grew its holdings in shares of Allergan by 1.5% during the second quarter. Toronto Dominion Bank now owns 517,895 shares of the company’s stock valued at $90,451,000 after buying an additional 7,683 shares in the last quarter. Finally, HL Financial Services LLC grew its holdings in shares of Allergan by 32.2% during the second quarter. HL Financial Services LLC now owns 601,456 shares of the company’s stock valued at $100,275,000 after buying an additional 146,645 shares in the last quarter. 77.43% of the stock is currently owned by institutional investors.
Shares of Allergan stock opened at $188.22 on Friday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 0.85 and a current ratio of 1.00. The firm has a market cap of $64.61 billion, a price-to-earnings ratio of 11.09, a price-to-earnings-growth ratio of 1.46 and a beta of 1.21. Allergan has a 1-year low of $142.81 and a 1-year high of $227.54.
Allergan (NYSE:AGN) last announced its earnings results on Thursday, July 26th. The company reported $4.42 earnings per share for the quarter, beating the consensus estimate of $4.13 by $0.29. Allergan had a positive return on equity of 8.60% and a negative net margin of 10.29%. The firm had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $3.92 billion. During the same quarter in the previous year, the business earned $4.02 EPS. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. research analysts forecast that Allergan will post 16.29 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Monday, September 17th. Stockholders of record on Friday, August 17th will be given a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.53%. The ex-dividend date is Thursday, August 16th. Allergan’s dividend payout ratio (DPR) is presently 17.61%.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.
Featured Story: How Do I Invest in Dividend Stocks
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.